Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Global Blood Ther
(NQ:
GBT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 4, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Global Blood Ther
< Previous
1
2
3
4
Next >
Biotech Stocks Well-Positioned For The Fourth Quarter
October 12, 2022
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
Via
Talk Markets
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
September 20, 2022
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022.
Via
Talk Markets
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Global Blood Therapeutics's Return On Capital Employed Overview
September 15, 2022
Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82.47 million, resulting in a 1.29% decrease from last quarter.
Via
Benzinga
Where Global Blood Therapeutics Stands With Analysts
August 09, 2022
Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings:
Via
Benzinga
Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics
August 08, 2022
The deal adds to Pfizer's efforts to tackle sickle cell disease.
Via
Investor's Business Daily
Pfizer Scoops Up Sickle Disease Player For $5B
August 08, 2022
Via
Benzinga
Global Blood Therapeutics's Return On Capital Employed Overview
September 01, 2022
Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $71.55 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 1.29%, resulting in a loss of $82.47...
Via
Benzinga
After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal
September 01, 2022
Via
Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
August 29, 2022
These names are benefitting from M&A, clinical data and promising regulatory actions.
Via
Investor's Business Daily
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
August 23, 2022
The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie.
Via
Investor's Business Daily
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
August 12, 2022
The major indexes continued to advance, despite some key warnings.
Via
Investor's Business Daily
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
August 09, 2022
Via
Benzinga
8 Analysts Have This to Say About Global Blood Therapeutics
August 09, 2022
Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
August 09, 2022
Via
Benzinga
Global Blood Therapeutics: Q2 Earnings Insights
August 08, 2022
Global Blood Therapeutics (NASDAQ:GBT) reported its Q2 earnings results on Monday, August 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
August 08, 2022
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT).
Via
Benzinga
TBLT, RDBX: The Top 5 Short Squeeze Stocks to Watch This Week
August 08, 2022
Short squeeze stocks are still a hot topic this week and we're listing five of the shares investors will want to keep an eye on!
Via
InvestorPlace
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics
August 08, 2022
GBT stock is already rallying on takeover talk. Now that Pfizer has confirmed the buyout, Global Blood Therapeutics is red hot.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
August 08, 2022
Via
Benzinga
Benzinga Before The Bell: Elon Musk Confirms Tesla AI Day Part 2, Dogecoin Scam, BioNTech Q2 Earnings Shocker And Other Top Financial Stories Monday, August 8
August 08, 2022
CNBC Celsius Withdraws Motion To Rehire CFO
Via
Benzinga
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
August 08, 2022
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
August 08, 2022
Gainers
Via
Benzinga
Small Cap Biotechs Perk Up On Dealmaking
August 06, 2022
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology.
Via
Talk Markets
12 Health Care Stocks Moving In Friday's Intraday Session
August 05, 2022
Via
Benzinga
A Preview Of Global Blood Therapeutics's Earnings
August 05, 2022
Global Blood Therapeutics (NASDAQ:GBT) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
August 05, 2022
Shares of Pfizer's rumored takeover target have rocketed for two days running.
Via
Investor's Business Daily
Pfizer, Global Blood Therapeutics In Advanced Talks For $5B Buyout Deal: Report
August 05, 2022
Pfizer Inc (NYSE: PFE) is reportedly in advanced talks to buy Global Blood Therapeutics Inc (NASDAQ: GBT) for about $5 billion, bolster its portfolio and pipeline.
Via
Benzinga
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
August 05, 2022
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share...
Via
Benzinga
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
August 05, 2022
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.